NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to ONO-4538 in Patients With Rhabdoid Tumor

NCT06622941

RecruitingPhase 2

Sponsor: Ono Pharmaceutical Co., Ltd.

Conditions: Rhabdoid Tumor

Interventions: ONO-4538

Countries: Japan

Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors

Eligibility overview

Sex: ALL

Age: 1 Year to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Gender: Not specified
2. Age (at the time of consent): 1 year or older
3. Patients who are refractory or intolerant to one or more regimens of chemotherapy for rhabdoid Tumors
4. Patients with advanced or recurrent rhabdoid Tumors not eligible for curative resection

Exclusion Criteria:

1. Patients with a history of active concurrent malignancy or complications
2. Patients with spinal lesions expected to require radiation therapy or surgical intervention during the trial period
3. Patients with concomitant central nervous system disorders other than AT/RT that are inadequately controlled or may lead to discontinuation of the investigational drug

Locations (14)

Nagoya, Aichi-ken, Japan
Sapporo, Hokkaido, Japan
Kobe, Hyōgo, Japan
Osaka, Osaka, Japan
Chuo-ku, Tokyo, Japan
Chiba, Japan
Fukuoka, Japan
Fukushima, Japan
Hiroshima, Japan
Kanazawa, Japan
Kyoto, Japan
Miyagi, Japan
Niigata, Japan
Tokyo, Japan